Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

69.00 +0.68 (+1.00%)
Streaming Delayed Price Updated: 1:23 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
A Look Ahead: Halozyme Therapeutics's Earnings Forecast ↗
 
Via Benzinga
News headline image
Unveiling 12 Analyst Insights On Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents. ↗
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout. ↗
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout. 
Via Chartmill
News headline image
Despite its growth, NASDAQ:HALO remains within the realm of affordability. ↗
Despite its growth, NASDAQ:HALO remains within the realm of affordability. 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is showing good growth, while it is not too expensive. ↗
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is not too expensive for the growth it is showing. ↗
NASDAQ:HALO is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
Top 2 Health Care Stocks That May Plunge In August ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Halozyme Therapeutics? ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying. 
Via Chartmill
News headline image
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
News headline image
(HALO) - Analyzing Halozyme Therapeutics's Short Interest ↗
 
Via Benzinga
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:HALO. ↗
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts ↗
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
Via Investor's Business Daily
News headline image
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
News headline image
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. ↗
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
3 Biotech Stocks on Track for 50% Returns (or More) by 2028 ↗
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.